GANX 8-K 2026-09-28
Gain Therapeutics, Inc. (GANX) 8-K dated 2026-09-28 — accession 0001104659-26-111391.
Gain Therapeutics, Inc. (GANX) is a biotechnology company listed on US.
Gain Therapeutics, Inc. filed a 8-K on 2026-09-28. Accession 0001104659-26-111391.
This 8-K covers: Director/officer change (Item 5.02). SEC EDGAR holds the official filing and its exhibits.
Latest reported GANX revenue for 2023-09-30 was $55.2K. Net income was -$4.7M. Revenue was up 0.0% from 2023-06-30 to 2023-09-30. GANX currently screens at market cap $53.0M.
Not investment advice. The GANX SEC hub lists recent forms. The stock page is the research view.